Navigation Links
VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
Date:11/8/2010

MOUNTAIN VIEW, Calif., Nov. 8, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today reported its financial results for the third quarter and nine months ended September 30, 2010.

Third Quarter HighlightsOn September 21, 2010, we announced top-line results from a two-year study of Qnexa which showed significant and sustained weight loss of greater than 10% over two years. Patients taking top- and mid-dose Qnexa achieved and maintained weight loss over two years of 11.4% and 10.4% of their initial body weight, respectively, as compared to placebo-treated patients with 2.5% weight loss (ITT-LOCF, p<0.0001). The findings come from the SEQUEL study (OB-305), a 52-week extension study for a subset of patients who completed the previously reported 56-week CONQUER study. The total study period was 108 weeks. SEQUEL included 675 obese or overweight patients, all of whom had two or more weight related co-morbidities, and an average baseline BMI of 36.1. Consistent with the first year experience, QNEXA therapy was well tolerated, with no new or unexpected adverse events. The most common side effects seen were constipation, tingling, dry mouth, altered taste and insomnia.

On October 1, 2010, we entered into a definitive asset purchase agreement with Meda to transfer our rights and assets related to MUSE, transurethral alprostadil, for the treatment of erectile dysfunction (ED).The acquisition price was $23.5 million, which includes an upfront cash payment of $22 million. The Company is eligible to receive a one-time milestone payment of $1.5 million based on future sales of MUSE. Meda has been our European distributor of MUSE since 2002. The assets sold include the United States and foreign MUSE patents, existing inventory and the manufacturing fa
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
2. VIVUS Announces Sale of MUSE Assets to Meda
3. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
4. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS Announces Promotion of Peter Tam to President
7. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
8. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
9. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
10. Anadys Pharmaceuticals Reports Third Quarter 2010 Financial Results and Highlights
11. GenVec Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013  IsoRay, Inc. (AMEX: ... has entered into an exclusive international distribution agreement with ... line in Greece . IsoRay is ... and medical radioisotope applications for brain cancer, lung cancer, ... cancer. IASIS Medical is ideally suited ...
(Date:5/21/2013)... Hurel Corporation ("Hurel"), a world-leading provider of ... today announced the appointment of James S. ... of Directors. Dr. MacDonald is the former Executive Vice ... ("SPRI"), which was the pharmaceutical development arm of Schering ... in 2009. Over a career that has ...
(Date:5/21/2013)... BioElectronics Corp. (PINKSHEETS: BIEL), the maker ... that CEO, Andrew J. Whelan ... Advisory Committee, Orthopedic and Rehabilitation Panel compelling arguments ... counter sales. "It,s been 37 years ... schema," Whelan said.  "While the old classification of ...
Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3
... N.J., Oct. 12 PharmaNet Development Group, Inc., ... innovative pharmaceutical, biotechnology, generic drug and medical device ... subsidiaries Anapharm and Taylor Technology will be showcasing ... AAPS Annual Meeting and Exposition. , Taylor ...
... Schering-Plough Corporation (NYSE: SGP ) is scheduled to ... quarter on Thursday, Oct. 22, 2009. , At ... a conference call to review results for the 2009 third ... members of management will host the conference call. , ...
Cached Medicine Technology:PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 2PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 3PharmaNet Development Group To Showcase Innovative Solutions and Poster Presentations at AAPS 2009 4Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings 2
(Date:5/21/2013)... Dallas, Texas (PRWEB) May 21, 2013 ... growth. Its expanding national presence has required the hiring ... , HealthSmart is pleased to announce that Dawn ... She is serving as the Director of Account Management ... HealthSmart Corporate offices in Irving, Texas. With extensive client ...
(Date:5/21/2013)... According to a May 13, 2013 New ... Botox,” Botox injections have become the most popular ... (Go to goo.gl/8iYbD). Although it is mostly associated with women, ... injection makes facial wrinkles less visible by paralyzing facial muscles. ... three months. This means that people who are conscious about ...
(Date:5/21/2013)... May 21, 2013 Global Proving Ground ... Bodybuilding.com, the largest online retailer of health and fitness ... reality-based sports show, Warrior Island. “We cast the ... Facebook & Twitter, with our unique social networking platform,” ... these elite fighters on an island in the Pacific ...
(Date:5/21/2013)... genetic features of pulmonary fibrosis by physicians and scientists ... lead to improved treatment of this deadly lung disease, ... . , The study found that a particular genetic ... fibrosis, a chronic progressive disease with a median survival ... researchers may want to consider including genetic testing in ...
(Date:5/21/2013)... May 21, 2013 The Las Vegas personal ... to announce that Crawford Gates, a senior at Coronado High ... college scholarship essay contest . As the winner of the ... essay contest started on Dec. 1, 2012 and ran through ... to submit a three-page minimum essay on “The Role of ...
Breaking Medicine News(10 mins):Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2
... 21 Talk About Curing Autism (TACA) is ... grant from the Newport Beach based Pacific Life Foundation. ... TACA will launch three new programs for Orange County, ... an in house advocate to provide education, training and ...
... Attorneys for The American Legion Department of Indiana have ... study cited by the Indiana State Department of Health ... the Indiana Soldiers, and Sailors, Children,s Home at Knightstown, ... Indiana,s Public Records Act, which requires the Department to ...
... linked to wind pattern that controls winter in Northern Hemisphere ... that flower buds are popping open earlier in the spring, ... , Not only have average worldwide temperatures been rising for ... year has shifted almost two days earlier. , That,s ...
... Jan. 21, 2009 Joslin Diabetes Center scientists are ... 2 diabetes to a new level with the launch of ... drug used for years to manage arthritis pain, can reduce ... successful, the trial could lead one day to an inexpensive ...
... ProvidersDALLAS, Jan. 21 Claimsnet.com (OTC ... MedAvant Healthcare Solutions (MedAvant) to provide a private ... MedAvant, we will be able to help our ... flow--a must in today,s market of tightening margins," ...
... popularity, it is critical for physicians to understand potential risks ... Company, the largest national insurer of physician and surgeon medical ... physicians successfully navigate telemedicine liability risks. , ... ...
Cached Medicine News:Health News:Talk About Curing Autism Receives $300,000 Grant From Pacific Life Foundation to Provide Services for Families Affected by Autism in Orange County 2Health News:Legion Attorneys Seek Copy of Health Department Study on Children's Home 2Health News:Seasons Arriving 2 Days Earlier, Study Says 2Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 2Health News:Joslin launches national study to explore if anti-inflammatory drug can treat type 2 diabetes 3Health News:MedAvant and Claimsnet Form Strategic Partnership 2Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 2Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 3Health News:The Doctors Company Provides Tips for Physicians to Minimize Risk While Practicing Medicine by Phone or E-mail 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: